دورية أكاديمية
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
| العنوان: | Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective |
|---|---|
| المؤلفون: | David J Brooks |
| المصدر: | Neuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 1, Pp 39-47 (2008) |
| بيانات النشر: | Dove Medical Press |
| سنة النشر: | 2008 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429 |
| الوصف: | David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite the recent emergence of a host of new therapies. Some physicians are cautious when prescribing levodopa because of its association with motor complications. Evidence now suggests that levodopa-associated complications are a result of deep troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]). Dosing strategies, such as dose increases and dose fractionation, may be effective in the short term. For the longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa therapy that significantly increases the plasma half-life and bioavailability of levodopa, providing more consistent plasma levodopa levels without deep troughs. Evidence from clinical trials in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently shown that levodopa/DDCI and entacapone significantly increases ON-time and affords greater functionality, as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) with conventional levodopa. These trials have also shown that levodopa/DDCI and entacapone is generally well tolerated, with notable adverse events including worsening dyskinesia, nausea and diarrhea. Patients experiencing re-emergence of symptoms due to wearing-off may benefit from optimized levodopa therapy with levodopa/carbidopa/entacapone.Keywords: levodopa, wearing-off, dyskinesia, entacapone, Stalevo |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1176-6328 1178-2021 |
| العلاقة: | http://www.dovepress.com/optimizing-levodopa-therapy-for-parkinsonrsquos-disease-with-levodopac-a994Test; https://doaj.org/toc/1176-6328Test; https://doaj.org/toc/1178-2021Test; https://doaj.org/article/97669d152cbb42ba97bbf2f8b725cd6fTest |
| الإتاحة: | https://doaj.org/article/97669d152cbb42ba97bbf2f8b725cd6fTest |
| رقم الانضمام: | edsbas.AB7287E0 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 11766328 11782021 |
|---|